ClinicalTrials.gg
CompletedNCT01137604Updated Sep 29, 2022Results posted

A Study in Subjects With Recurrent Malignant Glioma

A Phase 2 interventional study of Lenvatinib and Bevacizumab in Glioma, sponsored by Eisai Inc.. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-09-29.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 851 studies in Glioma with a site in United States — 142 open to participants now, 229 under way, 6 of them phase 3. Glioma · United States.

Enrollment
48th of 737
151 · median 30
Started
2010
with 36 others
Phase 2
227 of 851
21 open now
Registered
277th of 851
by date

Among the 851 studies in Glioma with a site in United States, this one is the 48th largest by enrollment of the 737 interventional ones that give a count, is one of 37 that started in 2010, is one of 227 in phase 2, and was the 277th registered.

Glioma

1,454 studies on the registry are indexed under Glioma; 350 are open to participants now.

Browse Glioma studies →

Open to participants now

142 of the 851 studies in Glioma with a site in United States are open now. Recruiting first, the newest first:

137 more — sign in →

All 142 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 56 (21%) stop at 75 or younger; 62 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 851 studies in Glioma with a site in United States, or all of them as a file.
02

Study summary

An open-label phase 2, multicenter study in participants with recurrent malignant glioma.

03

Conditions studied

  • Glioma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed diagnosis of Grade 3 or 4 malignant glioma.
  2. All subjects who have a first or second recurrence following primary management with surgical resection or , radiotherapy and up to 2 prior systemic treatments with addition of:

    • No prior bevacizumab treatment is allowed for Cohort 1 and Cohort 2.
    • Subjects must have disease progression following prior bevacizumab treatment for Cohort 3.
    • For all cohorts, no prior anti-vascular endothelial growth factor (VEGF/VEGFR) therapy except for bevacizumab as specified above.
  3. score of 70% or greater.
  4. Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than 150/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Screening Visit.
  5. Adequate renal function, adequate bone marrow function, adequate blood coagulation function and adequate liver function, as defined in protocol.
  6. No evidence of hemorrhage on the baseline magnetic resonance imaging (MRI) scan other than in those subjects who are stable grade 1.

Exclusion criteria

Exclusion criteria:

  1. Females who are pregnant or breastfeeding.
  2. Subjects who received enzyme-inducing anti-epileptic agents within 14 days before the first dose of study drug (eg, carbamazepine, phenytoin, phenobarbital, primidone, or oxcarbazepine).
  3. Active infection requiring intravenous antibiotics.
  4. Therapeutic anti-coagulation with warfarin, aspirin, nonsteroidal anti-inflammatory drugs or clopidogrel (low molecular weight heparin is acceptable).
  5. Subjects with 24-hour urine protein greater than or equal to 1 gm.
  6. Prior surgical resection within 4 weeks, or prior stereotactic within 2 weeks, of Screening Visit.
  7. Prior radiotherapy within 12 weeks unless there is a new area of enhancement consistent with recurrent tumor outside of the radiation field, or there is biopsy-proven unequivocal viable tumor on histopathologic sampling.
  8. Prior chemotherapy (6 weeks for nitrosoureas), or any agent within 4 weeks unless the subject has recovered from all anticipated toxicities associated with that therapy; prior bevacizumab therapy (Cohorts 1 and 2); for Cohort 3, prior bevacizumab therapy within 3 weeks.
  9. Significant cardiovascular impairment: history of congestive heart failure greater than (NYHA) Class II ; unstable angina; myocardial infarction or stroke within 6 months of the first dose of study drug; or cardiac arrhythmia requiring medical treatment.
  10. Prolongation of to greater than 480 msec.
  11. Active hemoptysis (bright red blood of at least 1/2 teaspoon) within 3 weeks prior to the first dose of study drug.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Cohort 1 assessed participants with recurrent Grade 4 malignant glioma (ie, glioblastoma \[GBM\]) who were bevacizumab-naive. Participants were planned to be accrued in Cohort 1 and randomized in a 1:1 ratio to receive lenvatinib (experimental) or bevacizumab (active comparator). Cohort 1 - Bevacizumab Cohort 1 - Lenvatinib

    Drug: Lenvatinib · Drug: Bevacizumab

  • Experimental
    Cohort 2

    Cohort 2 assessed participants with recurrent Grade 3 malignant glioma who were bevacizumab-naive. Participants in Cohort 2 were planned to be treated with lenvatinib.

    Drug: Lenvatinib

  • Experimental
    Cohort 3

    Cohort 3 assessed participants with recurrent GBM who had disease progression following prior bevacizumab treatment. Participants in Cohort 3 were planned to be treated with lenvatinib.

    Drug: Lenvatinib

Interventions

  • 24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.

    Also known as: E7080

  • Bevacizumab 10 mg/kg administered intravenously every 2 weeks in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Rate at Month 6

    PFS at Month 6 was defined as the percentage of participants who remained alive and progression-free at Month 6, based on investigator's assessment. Progression was defined using Response Assessment in Neuro-Oncology (RANO) criteria, as a greater than 25% increase in enhancing lesions despite stable or increasing steroid dose, an increase (significant) in non-enhancing T2-weighted-Fluid-Attenuated Inversion Recovery (T2/FLAIR) lesions that are not attributable to other non-tumor causes, and any new lesions. PFS rate at Month 6 was estimated from Kaplan-Meier (K-M) product-limit estimate of PFS.

    Time frame: At Month 6 from randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3)

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR was the percentage of participants with best overall response (BOR) of complete response (CR) and partial response (PR) based on RANO criteria and investigator's assessment. CR was defined as the disappearance of all enhancing disease (measurable and non-measurable) sustained for at least 4 weeks, no new lesions, and stable or improved non-enhancing (T2/FLAIR) lesions. PR was defined as greater than or equal to 50% decrease, compared to baseline, in the sum of products of perpendicular diameters of all measureable enhancing lesions sustained for at least 4 weeks. No progression of non-measurable disease, no new lesions, stable or improved non-enhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared to baseline. For both CR and PR, in the absence of a confirming scan 4 weeks later, this scan was considered only stable disease. Only participants with measureable disease at baseline were included in evaluation of ORR.

    Time frame: From date of randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3) until disease progression, development of unacceptable toxicity, withdrawal of consent or up to data cutoff date of 19 March 2013 (i.e., 2.4 years)

  2. Progression Free Survival

    PFS was measured as the time from randomization (Cohort 1) or the first day of treatment (Cohorts 2 and 3) until the date of first documentation of disease progression or date of death, if death occurred prior to disease progression, based on investigator's assessment.

    Time frame: From date of randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3) until disease progression, development of unacceptable toxicity, withdrawal of consent or up to data cutoff date of 19 March 2013 (ie, 2.4 years)

  3. Overall Survival (OS)

    OS was measured as the time from the randomization date (Cohort 1) or the first day of treatment (Cohort 2 and 3) to the date of death from any cause.

    Time frame: From date of randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3) until death due to any cause or up to data cutoff date of 19 March 2013 (ie, 2.4 years)

  4. Disease Control Rate (DCR)

    DCR was the percentage of the participants who had BOR of CR, PR, and stable disease (SD) with the minimum duration of SD lasting greater than or equal to 7 weeks. Only participants with measurable disease at baseline were included in evaluation of DCR, based on investigator's assessment.

    Time frame: From date of randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3) until disease progression, development of unacceptable toxicity, withdrawal of consent or up to data cutoff date of 19 March 2013 (ie, 2.4 years)

  5. Clinical Benefit Rate (CBR)

    CBR was the percentage of the participants who had BOR of CR, PR, and SD with the minimum duration of SD lasting greater than or equal to 23 weeks. Only participants with measurable disease at baseline were included in evaluation of CBR, based on investigator's assessment.

    Time frame: From date of randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3) until disease progression, development of unacceptable toxicity, withdrawal of consent or up to data cutoff date of 19 March 2013 (ie, 2.4 years)

  6. Number of Participants With Adverse Events (AEs)/Serious Adverse Events (SAEs) as a Measure of Safety

    Safety was assessed by monitoring and recording all AEs including all Common Terminology Criteria for Adverse Events (CTCAE) grades (for both increasing and decreasing severity) and SAEs; regular monitoring of hematology, clinical chemistry, and urine values; results of physical examinations, regular measurement of vital signs, and electrocardiograms (ECGs), as detailed in the Schedule of Visits and Procedures. The relationship of AEs to treatment was based on investigator judgment. Details of AEs and SAEs are provided in the reported adverse event section.

    Time frame: For each participant, from the first patient first dose till 30 days after the last dose or the cut-off date of 19 March 2013 (ie, 2.4 years)

07

Results

Posted May 23, 2016

Participant flow

A total of 173 participants were screened and of those, 152 participants were deemed eligible, and 151 received study treatment.

Participant flow — Overall Study
MilestoneCohort 1 - BevacizumabCohort 1 - LenvatinibCohort 2 - LenvatinibCohort 3 - Lenvatinib
Started38423932
Treatment discontinued due to disease progression34322621
Completed34322621
Not completed4101311
Withdrew: Adverse event3699
Withdrew: Participant choice0220
Withdrew: Withdrawal of consent0002
Withdrew: Clinical progression/deterioration1220

Outcome measures

SecondaryObjective Response Rate (ORR)

ORR was the percentage of participants with best overall response (BOR) of complete response (CR) and partial response (PR) based on RANO criteria and investigator's assessment. CR was defined as the disappearance of all enhancing disease (measurable and non-measurable) sustained for at least 4 weeks, no new lesions, and stable or improved non-enhancing (T2/FLAIR) lesions. PR was defined as greater than or equal to 50% decrease, compared to baseline, in the sum of products of perpendicular diameters of all measureable enhancing lesions sustained for at least 4 weeks. No progression of non-measurable disease, no new lesions, stable or improved non-enhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared to baseline. For both CR and PR, in the absence of a confirming scan 4 weeks later, this scan was considered only stable disease. Only participants with measureable disease at baseline were included in evaluation of ORR.

Time frame:
From date of randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3) until disease progression, development of unacceptable toxicity, withdrawal of consent or up to data cutoff date of 19 March 2013 (i.e., 2.4 years)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsCohort 1 - BevacizumabCohort 1 - LenvatinibCohort 2 - LenvatinibCohort 3 - Lenvatinib
Objective Response Rate (ORR)15.8 (6.0 to 31.3)21.4 (10.3 to 36.8)7.7 (1.6 to 20.9)0.0 (0.0 to 10.9)
SecondaryProgression Free Survival

PFS was measured as the time from randomization (Cohort 1) or the first day of treatment (Cohorts 2 and 3) until the date of first documentation of disease progression or date of death, if death occurred prior to disease progression, based on investigator's assessment.

Time frame:
From date of randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3) until disease progression, development of unacceptable toxicity, withdrawal of consent or up to data cutoff date of 19 March 2013 (ie, 2.4 years)
Reported as:
Median · Months
Progression Free Survival
MonthsCohort 1 - BevacizumabCohort 1 - LenvatinibCohort 2 - LenvatinibCohort 3 - Lenvatinib
Progression Free Survival2.8 (1.9 to 3.6)2.4 (1.8 to 3.6)2.8 (1.9 to 3.7)1.8 (1.0 to 2.5)
SecondaryOverall Survival (OS)

OS was measured as the time from the randomization date (Cohort 1) or the first day of treatment (Cohort 2 and 3) to the date of death from any cause.

Time frame:
From date of randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3) until death due to any cause or up to data cutoff date of 19 March 2013 (ie, 2.4 years)
Reported as:
Median · Months
Overall Survival (OS)
MonthsCohort 1 - BevacizumabCohort 1 - LenvatinibCohort 2 - LenvatinibCohort 3 - Lenvatinib
Overall Survival (OS)6.0 (4.5 to 7.7)7.5 (5.6 to 11.6)12.0 (8.4 to NA)4.1 (3.0 to 5.9)
SecondaryDisease Control Rate (DCR)

DCR was the percentage of the participants who had BOR of CR, PR, and stable disease (SD) with the minimum duration of SD lasting greater than or equal to 7 weeks. Only participants with measurable disease at baseline were included in evaluation of DCR, based on investigator's assessment.

Time frame:
From date of randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3) until disease progression, development of unacceptable toxicity, withdrawal of consent or up to data cutoff date of 19 March 2013 (ie, 2.4 years)
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsCohort 1 - BevacizumabCohort 1 - LenvatinibCohort 2 - LenvatinibCohort 3 - Lenvatinib
Disease Control Rate (DCR)57.9 (40.8 to 73.7)50.0 (34.2 to 65.8)48.7 (32.4 to 65.2)28.1 (13.7 to 46.7)
SecondaryClinical Benefit Rate (CBR)

CBR was the percentage of the participants who had BOR of CR, PR, and SD with the minimum duration of SD lasting greater than or equal to 23 weeks. Only participants with measurable disease at baseline were included in evaluation of CBR, based on investigator's assessment.

Time frame:
From date of randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3) until disease progression, development of unacceptable toxicity, withdrawal of consent or up to data cutoff date of 19 March 2013 (ie, 2.4 years)
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR)
Percentage of participantsCohort 1 - BevacizumabCohort 1 - LenvatinibCohort 2 - LenvatinibCohort 3 - Lenvatinib
Clinical Benefit Rate (CBR)15.8 (6.0 to 31.3)26.2 (13.9 to 42.0)17.9 (7.5 to 33.5)6.3 (0.8 to 20.8)
SecondaryNumber of Participants With Adverse Events (AEs)/Serious Adverse Events (SAEs) as a Measure of Safety

Safety was assessed by monitoring and recording all AEs including all Common Terminology Criteria for Adverse Events (CTCAE) grades (for both increasing and decreasing severity) and SAEs; regular monitoring of hematology, clinical chemistry, and urine values; results of physical examinations, regular measurement of vital signs, and electrocardiograms (ECGs), as detailed in the Schedule of Visits and Procedures. The relationship of AEs to treatment was based on investigator judgment. Details of AEs and SAEs are provided in the reported adverse event section.

Time frame:
For each participant, from the first patient first dose till 30 days after the last dose or the cut-off date of 19 March 2013 (ie, 2.4 years)
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs)/Serious Adverse Events (SAEs) as a Measure of Safety
ParticipantsCohort 1 - BevacizumabCohort 1 - LenvatinibCohort 2 - LenvatinibCohort 3 - Lenvatinib
AEs38403932
SAEs9201215
PrimaryProgression Free Survival (PFS) Rate at Month 6

PFS at Month 6 was defined as the percentage of participants who remained alive and progression-free at Month 6, based on investigator's assessment. Progression was defined using Response Assessment in Neuro-Oncology (RANO) criteria, as a greater than 25% increase in enhancing lesions despite stable or increasing steroid dose, an increase (significant) in non-enhancing T2-weighted-Fluid-Attenuated Inversion Recovery (T2/FLAIR) lesions that are not attributable to other non-tumor causes, and any new lesions. PFS rate at Month 6 was estimated from Kaplan-Meier (K-M) product-limit estimate of PFS.

Time frame:
At Month 6 from randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3)
Reported as:
Number · Percentage of participants
Progression Free Survival (PFS) Rate at Month 6
Percentage of participantsCohort 1 - BevacizumabCohort 1 - LenvatinibCohort 2 - LenvatinibCohort 3 - Lenvatinib
Progression Free Survival (PFS) Rate at Month 611.0 (3.5 to 23.4)21.2 (10.4 to 34.5)8.0 (1.6 to 21.6)7.6 (1.3 to 21.5)

Adverse events

Collected over For each participant, from the first patient first dose till 30 days after the last dose or the cut-off date of 19 March 2013 (ie, 2.4 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 - Bevacizumab36/38 (94.7%)10/38 (26.3%)38/38 (100%)
Cohort 1 - Lenvatinib38/42 (90.5%)22/42 (52.4%)40/42 (95.2%)
Cohort 2 - Lenvatinib27/39 (69.2%)12/39 (30.8%)39/39 (100%)
Cohort 3 - Lenvatinib30/32 (93.8%)15/32 (46.9%)31/32 (96.9%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventCohort 1 - BevacizumabCohort 1 - LenvatinibCohort 2 - LenvatinibCohort 3 - Lenvatinib
ConvulsionNervous system disorders2/385/421/392/32
PneumoniaInfections and infestations2/380/420/391/32
Wound dehiscenceInjury, poisoning and procedural complications2/380/420/390/32
FatigueGeneral disorders0/380/422/390/32
HeadacheNervous system disorders0/381/422/390/32
HypothyroidismEndocrine disorders0/382/420/390/32
VomitingGastrointestinal disorders0/382/420/391/32
General physical health deteriorationGeneral disorders0/382/420/390/32
Cerebrovascular accidentNervous system disorders0/382/420/390/32
Abdominal painGastrointestinal disorders1/380/420/391/32
Most frequent other events
Showing 10 of 117
Most frequent other events
EventCohort 1 - BevacizumabCohort 1 - LenvatinibCohort 2 - LenvatinibCohort 3 - Lenvatinib
FatigueGeneral disorders21/3825/4225/3914/32
HypertensionVascular disorders14/3821/4217/3915/32
HeadacheNervous system disorders13/386/4212/3913/32
DysphoniaRespiratory, thoracic and mediastinal disorders4/3814/4211/399/32
DiarrhoeaGastrointestinal disorders7/387/4211/3910/32
ProteinuriaRenal and urinary disorders2/386/424/399/32
NauseaGastrointestinal disorders10/386/428/395/32
HypothyroidismEndocrine disorders1/387/4210/394/32
Muscular weaknessMusculoskeletal and connective tissue disorders4/388/4210/394/32
AphasiaNervous system disorders9/384/422/395/32

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1 - BevacizumabCohort 1 - LenvatinibCohort 2 - LenvatinibCohort 3 - LenvatinibTotal
Mean55.1 ± 10.6155.5 ± 11.9649.2 ± 11.3553.0 ± 11.1552.6 ± 11.74
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 - BevacizumabCohort 1 - LenvatinibCohort 2 - LenvatinibCohort 3 - LenvatinibTotal
Female1313101450
Male25292918101
World Health Organization Grading for Gliomas
World Health Organization Grading for Gliomas(Participants)Cohort 1 - BevacizumabCohort 1 - LenvatinibCohort 2 - LenvatinibCohort 3 - LenvatinibTotal
Grade 30039039
Grade 43842032112
08

Study locations

5 sites
  • Tampa, Florida, United States
  • Boston, Massachusetts, United States
  • Durham, North Carolina, United States
  • Calgary, Canada
  • Toronto, Canada
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2010 to primary completion in Mar 2013, 28 months.

Results were first posted in May 2016, 3 years 2 months after primary completion.

Of 131 phase 2 interventional studies under Glioma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 88. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2010
First posted
Jun 4, 2010
StartActual
Nov 9, 2010
Primary completionActual
Mar 19, 2013
CompletionActual
Oct 28, 2014
Results first posted
May 23, 2016
Last update
Sep 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01137604
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jun 4, 2010
Start date
Nov 9, 2010
Primary completion
Mar 19, 2013
Completion
Oct 28, 2014
Results posted
May 23, 2016
Last update
Sep 29, 2022

Study contacts

Eisai Medical Services
study director · Eisai Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion